Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AORT vs UFPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: AORT 1 – 5 UFPT Matrix Metrics: AORT 2 – 8 UFPT

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Artivion, Inc. (AORT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AORT carries a Unified Composite Score of 45.4/100 (HOLD) at $18.47 (35.5x Forward P/E, 7.6% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).

  • Composite vs. Pillar Nuance: While AORT currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 7.6% operating margin) and revenue trajectory (+11.6% vs. +9.2% YoY).
  • Technical & Structure Timing Caution: AORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.4); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AORT vs UFPT
AORT NYSE
Artivion, Inc.
Surgical & Medical Instruments & Apparatus
$18.47
-3.3% 1D
Market Cap $931.9M
TTM Revenue $482M
Forward P/E 35.5x
Beta / 30D Vol 0.45β · 92% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $22.27 · SMA50: $22.74
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17

6-Pillar Scorecard Institutional Category Breakdown (AORT 1 – 5 UFPT)

Columns: Metric · AORT · UFPT
1. Valuation Multiples UFPT
Forward P/E 35.5x 24.7x
Trailing P/E 30.2x 31.2x
PEG Ratio N/M 3.80x
EV / Revenue 2.7x 3.6x
2. Growth & Scale UFPT
Revenue Growth (YoY) +9.2% +11.6%
Earnings Growth (YoY) +0.0% +25.1%
TTM Revenue (USD) $482M $650M
Market Cap $931.9M $2.4B
3. Profitability & Quality UFPT
Gross Margin 63.3% 28.9%
Operating Margin 7.6% 15.4%
Net Profit Margin -3.6% 11.8%
Return on Equity (ROE) -4.0% 17.2%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) -$44M $120M EBITDA
Cash Flow Margin -9.2% 18.5% EBITDA Mgn
Net Cash / Leverage $359M Net Debt (0.91x D/E) $62.70 Book/Sh · 17.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning UFPT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.7% (20th %ile) 42.3% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat AORT
OpEx & R&D Intensity 55.7% of Rev ($268M) 13.5% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AORT (2) vs UFPT (8)
Institutional Metric AORT UFPT Criterion Row Edge
Market Capitalization
Scale
$931.9M $2.4B Larger Scale UFPT
Trailing P/E Ratio
Valuation
30.2x 31.2x Lower Multiple AORT
Forward P/E Ratio
Valuation
35.5x 24.7x Lower Multiple UFPT
Revenue Growth (YoY)
Growth
+9.2% +11.6% Higher Growth UFPT
Operating Margin (TTM)
Profitability
7.6% 15.4% Higher Margin UFPT
Net Profit Margin
Profitability
-3.6% 11.8% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
-4.0% 17.2% Higher ROE UFPT
52-Week Range Position
Momentum
1% ($18–$48) 74% ($174–$342) Stronger Trend UFPT
Beta / 30D Volatility
Risk Regime
0.45β · 92% Vol 1.64β · 77% Vol Lower Realized Risk UFPT
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite AORT
Trailing 12M Revenue (USD)
Operating Scale
$482M $650M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.3% 28.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.7x EV/Rev 3.80x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($359M Net Debt (0.91x D/E)) $120M EBITDA ($62.70 Book/Sh · 17.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UFPT +17.56 pp
AORT: -15.2% · UFPT: +2.36%
3M Horizon UFPT +31.17 pp
AORT: -36.09% · UFPT: -4.92%
6M Horizon UFPT +59.7 pp
AORT: -22.26% · UFPT: +37.44%
1Y Horizon UFPT +86.91 pp
AORT: -59.49% · UFPT: +27.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AORT vs UFPT. Trailing 12-month operating profitability (AORT 7.6% vs UFPT 15.4%) and valuation multiples (AORT 35.5x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.

AORT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$482M
Gross Margin63.3%
Op. Margin7.6%
ROE / Fwd P/E-4.0% · 35.5x
UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AORT BREAKDOWN
65d in phase · OBV DISTRIBUTION
Current IV 111.7%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact AORT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AORT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $931.9M market capitalization and 7.6% operating margin.
OpEx & R&D Reinvestment 55.7% of Rev ($268M)
90D Engineering Disclosures 0 Published
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ AORT vs UFPT Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Artivion, Inc. (AORT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AORT carries a Unified Composite Score of 45.4/100 (HOLD) at $18.47 (35.5x Forward P/E, 7.6% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Composite vs. Pillar Nuance: While AORT currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 7.6% operating margin) and revenue trajectory (+11.6% vs. +9.2% YoY). Technical & Structure Timing Caution: AORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.4); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: AORT posts +9.2% YoY revenue growth and +0.0% YoY earnings growth on $482M TTM revenue (63.3% gross margin, 7.6% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, AORT generates $482M in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, AORT deploys 55.7% of Rev ($268M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.

UFPT screens cheaper on headline valuation multiples. AORT trades at 35.5x Forward P/E, 30.2x Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-9.2% FCF margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AORT (-4.0% ROE) versus UFPT (17.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AORT carries 111.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 92% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.